6. Adapting to Change: Is Your Pharma Commercial Strategy Ready for the Future?
Your tried and true commercial strategy has worked for decades — you may feel at ease, but with the emergence of AI in our doctors' offices and hospitals, things have changed. Decades ago, a sizable field force played a significant role in biopharma commercial strategy, with sales reps being the first line into prescriber education, influence, and decision-making. However, as healthcare evolves, so too must pharma’s gameplan, placing less emphasis on in-person interactions and more on sophisticated technologies, including AI. In August’s edition of Innovizion, we explore how pharma’s commercial strategies must adapt to the modern AI-powered healthcare continuum.
?? The Latest
With technology shaping our daily lives, why should biopharma's strategy be any different? Commercial leaders in biopharma must modernize, moving away from traditional methods to meet the needs of today's clinicians and patients. Tools like AI-powered care coordination from Viz.ai are revolutionizing healthcare. How will biopharma adapt?
?? Hypertrophic cardiomyopathy (HCM), often referred to as “the great masquerader,” ?? goes undiagnosed in 85% of cases. In the latest edition of NEJM AI , Dr. Matthew Martinez , Director of the HCM and Sports Cardiology Program at Morristown Medical Center/ Atlantic Health System , discusses the challenges and opportunities for enhancing HCM diagnosis using artificial intelligence. Read Dr. Martinez's perspective to understand how combining AI with ECG analysis and care coordination (Viz HCM) can lift the mask, revealing hidden cases and streamlining the patient journey.
?? Viz News
?? We received award nominations from Firece Pharma and PM360 for our HCM solution. Viz HCM was developed in partnership with a leading pharmaceutical company, and these awards are a testament to our strong partnership with industry.
?? We proudly announced that the Viz.ai One Platform has achieved seven ISO certifications, including ISO-27001:2022. Achieving this rigorous auditing standard further validates Viz.ai as trusted and secure for health systems. This announcement follows our successful completion of a SOC 2 Type 2 + HIPAA audit.
?? Vizion
?? Read Gaurav Singal, MD ’s latest opinion: It's not just hype. AI could revolutionize diagnosis in medicine.?
??Cardiology AI algorithms are on the rise, with 135 currently FDA cleared. Find the FDA report and Cardiovascular Business ’s analysis here. With this increase, the FDA has appointed a Cardiologist to head a new FDA advisory committee focused on AI, other digital health technologies.
A study conducted at Mount Sinai Health System in New York ??? found that hospitalized patients were 43% more likely to have their care escalated and significantly less likely to die if their care team received AI-generated alerts signaling adverse changes in their health. Read more in the news story and clinical study.
Accurate and early detection are the cornerstones of effective treatment.??Cardiac amyloidosis, once considered rare and deadly, is now known to be more common due to better detection, using ECG and echo capabilities. Viz.ai received the first De Novo approval by the FDA for an AI algorithm for hypertrophic cardiomyopathy (HCM) using ECG to identify suspected cases. Read about the potential of using ECG AI —?and echo — to find the cardiac amyloidosis needles in the haystack.
??KOL Perspective
?? Jonathan A. Aliota, MD, MS FACC , an Interventional Cardiologist in Houston, TX, offers insights into AI's transformative impact on patient care. AI's value not only lies in helping to save costs for the healthcare system but also in detecting diseases earlier and subsequently initiating and deploying the appropriate therapy — 'which could mean the difference between life and death,' says Dr. Aliota.
?? Events
?? European Society of Cardiology | August 30 - September 1
Meet with Karel Gless and Jack Manley, MD in London, UK. Reach out to Anne Hellie to join our exclusive event.
?? Digital Pharma East | September 9-12
Join Jack Manley, MD , Head of New Markets & Growth at Viz.ai , as he speaks on the panel: Tailored Connections: The Power of Personalization in HCP Marketing
When: Wednesday September 11, 2024 @ 10:15 am - 11:00 am ET?@ Digital Pharma East
Moderator: Nandini Nayar Global Digital Health and Innovation Lead, Sanofi
Panelists:
Kamya Elawadhi SVP- Platform & Corporate Strategy, Doceree
Lori Holland-Hancock Director Channel Strategy & Engagement Team, Oncology, 默克
Jack Manley, MD Head of New Markets and Growth, Viz.ai
Gunjan Aggarwal Executive Director | Head - Data Strategy and Marketing Data Solutions, 诺华
Silvia Schneiders Filippi Director of Marketing, Halozyme, Inc.
??? Contributors
Get in touch with Tom Krohn and Sherie Zhou
Copyright ? 2024 Viz.ai
548 Market St., # 21826, San Francisco, CA 94104
Between issues, keep current with the latest updates from Viz.ai by following us on LinkedIn and by subscribing to the exclusive email version of Innovizion, sent bi-monthly directly to your inbox from Team Viz.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.